Summarized by Masters of Longevity from Longevity Technology.
A brief news article about a biotech company's launch of a first-in-human trial for a new brain-penetrant small-molecule drug, highlighting study intent and pipeline context.
Key Takeaways
- Tenvie dosed the first subject in a Phase 1 randomized ascending dose trial of TNV313.
- The trial will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single and multiple oral doses.
- TNV313 is presented as a fully CNS-penetrant small molecule NLRP3 inhibitor joining a second clinical-stage CNS NLRP3 asset in the company pipeline.
